NCT02212249View on ClinicalTrials.gov

Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis

NACompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Primary Raynaud DiseaseSystemic Sclerosis
Interventions
BIOLOGICAL

soluble Ve cadherin

dosage of soluble VE cadherine in each arms

Trial Locations (1)

38043

Grenoble University Hospital, Grenoble

All Listed Sponsors
lead

University Hospital, Grenoble

OTHER

NCT02212249 - Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis | Biotech Hunter | Biotech Hunter